Related Experiment Video
Updated: Mar 10, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32β transgenic mice
Yu Yeon Jung1, Nikita Katila2, Sabita Neupane2
1Department of Dental Hygiene, Gwang Yang Health College, Gwangyang 57764, Republic of Korea.
Abstract:
Parkinson's disease (PD) is a neurodegenerative disorder characterized by prominent loss of the nigral dopaminergic neurons and motor symptoms, such as resting tremor and bradykinesia. Evidence suggests that neuroinflammation may play a critical role in PD pathogenesis. Interleukin (IL)-32 is a newly-identified proinflammatory cytokine, which regulates innate and adaptive immune responses by activating p38 MAPK and NF-κB signaling pathways. The cytokine has been implicated in cancers and autoimmune, inflammatory, and infectious diseases. In this study, we attempted to identify the effects of IL-32β on dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), using IL-32β transgenic mice. Male wild type and IL-32β transgenic mice received intraperitoneal injections of vehicle or MPTP (15 mg/kg × 4). Immunohistochemistry showed that overexpression of IL-32β significantly increased MPTP-mediated loss of dopaminergic neurons in the substantia nigra and deletion of tyrosine hydroxylase-positive fibers in the striatum. Dopamine depletion in the striatum and deficit in locomotor activity were enhanced in IL-32β transgenic mice. These results were accompanied by higher neuroinflammatory responses in the brains of transgenic mice. Finally, we found that IL-32β exaggerated MPTP-mediated activation of p38 MAPK and JNK pathways, which have been shown to be involved in MPTP neurotoxicity. These results suggest that IL-32β exacerbates MPTP neurotoxicity through enhanced neuroinflammatory responses.
Insights
Interleukin-32 beta (IL-32β) worsens Parkinson's disease (PD) models by increasing neuroinflammation and dopaminergic neuron loss. This suggests IL-32β exacerbates MPTP neurotoxicity via inflammatory pathways.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Parkinson's disease (PD) involves dopaminergic neuron loss and neuroinflammation.
- Interleukin-32 (IL-32) is a pro-inflammatory cytokine implicated in various diseases.
- IL-32 regulates immune responses via p38 MAPK and NF-κB pathways.
Purpose of the Study:
- To investigate the effect of Interleukin-32 beta (IL-32β) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity.
- To determine if IL-32β exacerbates dopaminergic neurodegeneration and associated neuroinflammation.
Main Methods:
- Utilized IL-32β transgenic mice and wild-type littermates.
- Administered MPTP (15 mg/kg x 4) or vehicle intraperitoneally.
- Performed immunohistochemistry to assess dopaminergic neuron loss and tyrosine hydroxylase-positive fiber deletion.
- Measured dopamine levels, locomotor activity, and neuroinflammatory markers.
- Analyzed p38 MAPK and JNK pathway activation.
Main Results:
- Overexpression of IL-32β significantly increased MPTP-induced loss of dopaminergic neurons in the substantia nigra.
- IL-32β transgenic mice showed enhanced dopamine depletion and locomotor deficits.
- MPTP treatment led to heightened neuroinflammatory responses in IL-32β transgenic mice.
- IL-32β exacerbated MPTP-mediated activation of p38 MAPK and JNK signaling pathways.
Conclusions:
- IL-32β overexpression exacerbates MPTP-induced dopaminergic neurotoxicity.
- Enhanced neuroinflammation and activation of MAPK pathways (p38 and JNK) are key mechanisms.
- IL-32β may represent a novel therapeutic target for mitigating Parkinson's disease progression.
